DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 1, 2008; DOI: 10.1124/dmd.108.024745


0090-9556/09/3703-635-643$20.00
DMD 37:635-643, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.024745v1
37/3/635    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Syvänen, S.
Right arrow Articles by Hammarlund-Udenaes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Syvänen, S.
Right arrow Articles by Hammarlund-Udenaes, M.

Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport

Stina Syvänen, Örjan Lindhe, Mikael Palner, Birgitte R. Kornum, Obaidur Rahman, Bengt Långström, Gitte M. Knudsen, and Margareta Hammarlund-Udenaes

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (S.S., M.H.-U.); Uppsala Imanet, GE Healthcare, Uppsala, Sweden (S.S., Ö.L.); Uppsala Applied Science Lab, GEMS PET Systems, GE Healthcare, Uppsala, Sweden (O.R., B.L.); Neurobiology Research Unit, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark (M.P., B.R.K., G.M.K.); and Department of Biochemistry and Organic Chemistry, Uppsala University, Uppsala, Sweden (B.L.)

Species differences occur in the brain concentrations of drugs, but the reasons for these differences are not yet apparent. This study was designed to compare brain uptake of three radiolabeled P-glycoprotein (P-gp) substrates across species using positron emission tomography. Brain concentrations and brain-to-plasma ratios were compared; [11C]verapamil in rats, guinea pigs, and monkeys; [11C](S)-(2-methoxy-5-(5-trifluoromethyltetrazol-1-yl)-phenylmethylamino)-2(S)-phenylpiperidine (GR205171) in rats, guinea pigs, monkeys, and humans; and [18F]altanserin in rats, minipigs, and humans. The fraction of the unbound radioligand in plasma was studied along with its metabolism. The effect of P-gp inhibition was investigated by administering cyclosporin A (CsA). Pronounced species differences were found in the brain and brain-to-plasma concentrations of [11C]verapamil, [11C]GR205171, and [18F]altanserin with higher brain distribution in humans, monkeys, and minipigs than in rats and guinea pigs. For example, the brain-to-plasma ratio of [11C]GR205171 was almost 9-fold higher in humans compared with rats. The species differences were still present after P-gp inhibition, although the increase in brain concentrations after P-gp inhibition was somewhat greater in rats than in the other species. Differences in plasma protein binding and metabolism did not explain the species-related differences. The findings are important for interpretation of brain drug delivery when extrapolating preclinical data to humans. Compounds found to be P-gp substrates in rodents are likely to also be substrates in higher species, but sufficient blood-brain barrier permeability may be retained in humans to allow the compound to act at intracerebral targets.


Address correspondence to: Dr. Stina Syvänen, Division of Pharmacology, Leiden University, Leiden-Amsterdam Center for Drug Research (LACDR), Box 9502, 2300 RA Leiden, The Netherlands. E-mail: s.syvanen{at}lacdr.leidenuniv.nl







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.